The importance and method of anticoagulation in  the treatment of pulmonary thromboembolism       LI Yan-xia, ZHANG Zhong-he. The First Affiliated Hospital of Dalian Medical University, Dalian116011, China
Corresponding author: ZHANG Zhong-he, E-mail: medlbyby@vip.sina.com
Abstract    Pulmonary embolism (PE) is one of the common diseases in respiratory and cardiovascular emergencies. All PE patients should undergo rapid risk stratification (Grade 1C). For patients with evidence of hemodynamic compromise, we recommend use of thrombolytic therapy unless there are major contraindications owing to bleeding risk (Grade 1).Thrombolytic therapy is the important treatment for PE. For the majority of patients with PE, we recommend against using thrombolytic therapy. Anticoagulation is the basic treatment for PE. It is highly effective in reducing mortality and preventing recurrent VTE during treatment，and the bleeding risk is not high. Anticoagulant treatment plays a pivotal role in the management of patients with PE applying to various kinds of PE patients. Although of rapid onset, the haemodynamic benefits of thrombolysis over heparin appear to be confined to the first few days. One week after treatment, the changes in the severity of vascular obstruction and the reversal of RVD were no longer different between thrombolysis-treated and heparin-treated patients. However, anticoagulation methods differ when relate to special cases of PE during pregnancy ranges, PE combining tumor, heparin-induced thrombocytopenia, right heart thrombi, and etc.